16.04.2019
ZD Soft Video Recorder 1.0.3.0 serial key or number

ZD Soft Video Recorder 1.0.3.0 serial key or number

By  ZD Soft Video Recorder 1.0.3.0 serial key or number  0 Comments
ZD Soft Video Recorder 1.0.3.0 serial key or number

ZD Soft Video Recorder 1.0.3.0 serial key or number

Drug Discovery and Evaluation pp | Cite as

  • H. Gerhard Vogel
  • Wolfgang H. Vogel
  • Bernward A. Schölkens
  • Jürgen Sandow
  • Günter Müller
  • Wolfgang F. Vogel
  • 1Citations
  • Downloads

A.1 Cardiovascular analysis

A In vitro methods

A α1-adrenoreceptor binding

PURPOSE AND RATIONALE

α1 adrenoceptors are widely distributed and are activated either by norepinephrine released from sympathetic nerve terminals or by epinephrine released from the adrenal medulla. Receptor activation mediates a variety of functions, including contraction of smooth muscle, cardiac stimulation, cellular proliferation and activation of hepatic gluconeogenesis and glycolysis. In the CNS, the activation of α1 adrenoceptors results in depolarization and increased neuronal firing rate.

The α-adrenoreceptor population of plasma membranes from rat heart ventricles consists only of the α1-adrenoreceptor subtype. A constant concentration of the radioligand 3H-prazosin (– nM) is incubated with increasing concentrations of a non-labeled test drug ( mM–1 mM) in the presence of plasma membranes from rat heart ventricles. If the test drug exhibits any affinity to α-adrenoceptors, it is

Keywords

Adrenomedullin Left Ventricular Enddiastolic Pressure Spontaneously Hypertensive Rats Monophasic Action Potential (MAP) Millar Microtip Catheter 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

1With contributions to this and the first edition by B.A. Schölkens, H. Gögelein, F.P. Huger, W. Linz, K.A. Rudolphi, cromwellpsi.com

This is a preview of subscription content, log in to check access.

References

References

  1. Aboud R, Shafii M, Docherty JR () Investigation of the subtypes of α1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol –87PubMedGoogle Scholar
  2. Adolfo JA et al. () Species heterogeneity of hepatic α1-adrenoceptors: α1A-, α1B-, and α1C-subtypes. Biochem Biophys Res Comm –Google Scholar
  3. Ahlquist RP () A study of the adrenotropic receptors. Am J Physiol –PubMedGoogle Scholar
  4. Alexander S, Peters J, Mathie A, MacKenzie G, Smith A () TiPS Nomenclature Supplement Google Scholar
  5. Bylund DB, Eikenburg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U () IV. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol Rev –PubMedGoogle Scholar
  6. Bylund DB, Bond RA, Clarke DE, Eikenburg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Strosberg AD, Trendelenburg U () Adrenoceptors. The IUPHAR Compendium of Receptor Characterization and ClassificationGoogle Scholar
  7. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, Mostardini M, Schmidt A, Beermann F, Cotecchia S () Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc Natl Acad Sci USA –PubMedGoogle Scholar
  8. Cheng YC, Prusoff WH (). Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol –PubMedGoogle Scholar
  9. Endoh M, Takanashi M, Norota I () Role of alpha1A adrenoceptor subtype in production of the positive inotropic effect mediated via myocardial alpha1 adrenoceptors in the rabbit papillary muscle: influence of selective alpha1A subtype antagonists WB and 5-methylurapidil. Naunyn-Schmiedeberg's Arch Pharmacol –Google Scholar
  10. García-Sáinz JA () α1-adrenergic action: receptor subtypes, signal transduction and regulation. Cell Signal –PubMedGoogle Scholar
  11. García-Sáinz JA, Romero-Avila MT, Hernandez RA, Macias-Silva M, Olivares-Reyes A, González-Espinosa C () Species heterogeneity of hepatic α1-adrenoceptors: α1A-, α1B-and α1C-subtypes. Biochem Biophys Res Commun –PubMedGoogle Scholar
  12. Gleason MM, Hieble JP () The α2-adrenoreceptors of the human retinoblasoma cell line (Y79) may represent an additional example of the α2C-adrenoceptor. Br. J Pharmacol –PubMedGoogle Scholar
  13. Graham RM, Perez DM, Hawa J () Alphal adrenergic receptor subtypes. Molecular structure, function and signaling. Circ Res –PubMedGoogle Scholar
  14. Greengrass P, Bremner R () Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol –PubMedGoogle Scholar
  15. Guicheney P, Meyer P (). Binding of [3H]-prazosin and [3H]-dihydroergocryptine to rat cardiac α-adrenoceptors. Br J Pharmac –39Google Scholar
  16. Hieble JP, Ruffolo RR Jr () Recent advances in the identification of α1-and α2-adrenoceptor subtypes. Therapeutic implications. Expert Opin Invest Drugs –Google Scholar
  17. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr () International Union of Pharmacology: X. Recommendation for nomenclature of α1-adrenoceptors. Consensus update. Pharmacol Rev –PubMedGoogle Scholar
  18. Hoffman BB, de Lean A, Wood CL, Schocken DD, Lefkowitz RJ (). Alpha-adrenergic receptor subtypes: Quantitative assessment by ligand binding. Life Sci –PubMedGoogle Scholar
  19. Miach PJ, Dausse JP, Cardot A, Meyer P (). 3H-prazosin binds specifically to ‘α1'-adrenoceptors in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol –26Google Scholar
  20. Michel AD, et al. () Identification of a single α1A-adrenoceptor corresponding to the α1A-subtype in rat submaxillary gland. Br J Pharmacol –Google Scholar
  21. Minneman KP, Esbenshade TA () α1-adrenergic receptor subtypes. Ann Rev Pharmacol Toxicol –Google Scholar
  22. Ohmura T, Oshita M, Kigoshi S, Muramatsu I () Identification of α1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies. Br J Pharmacol –PubMedGoogle Scholar
  23. Oshita M, Kigoshi S, Muramatsu I () Pharmacological characterization of two distinct α1-adrenoceptor subtypes in rabbit thoracic aorta. Br J Pharmacol –PubMedGoogle Scholar
  24. Regan JW, Cotecchia S () The α-adrenergic receptors: new subtypes, pharmacology, and coupling mechanisms. In: Brann MR (ed) Molecular Biology of G-Protein-coupled receptors. Birkhäuser, Boston Basel Berlin, pp 76–Google Scholar
  25. Ruffolo RR, Stadel JM, Hieble JP () α-adrenoceptors: recent developments. Med Res Rev –Google Scholar
  26. Satoh M, Kojima C, Takayanagi I () Characterization of α1-adrenoceptor subtypes labeled by [3H]prazosin in single cells prepared from rabbit thoracic aorta. Eur J Pharmacol –41PubMedGoogle Scholar
  27. Schwinn DA, Lomasney JW () Pharmacologic characterization of cloned α1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype. Eur J Pharmacol — Mol Pharmacol Sect –Google Scholar
  28. Timmermans PBMWM, Karamat Ali F, Kwa HY, Schoop AMC, Slothorst-Grisdijk FP, van Zwieten PA () Identical antagonist selectivity of central and peripheral alpha1 adrenoceptors. Mol Pharmacol –PubMedGoogle Scholar
  29. Vargas HM, Cunningham D, Zhou L, Hartman HB, Gorman AJ () Cardiovascular effects of chloroethylclonidine, a irreversible α1B-adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro. J Pharm Exp Ther –Google Scholar
  30. Veenstra DMJ, van Buuren KJH, Nijkamp FP () Determination of α1-adrenoceptor subtype selectivity by [3H]-prazosin displacement studies in guinea-pig cerebral cortex and rat spleen membranes. Br J Pharmacol –PubMedGoogle Scholar

References

  1. Alexander S, Peters J, Mathie A, MacKenzie G, Smith A () TiPS Nomenclature Supplement Google Scholar
  2. Boyajian CL, Leslie FM () Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: Differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther –PubMedGoogle Scholar
  3. Brasch H () No influence of prejunctional α2-adrenoceptors on the effects of nicotine and tyramine in guinea-pig atria. J Auton Pharmacol –44PubMedGoogle Scholar
  4. Broadhurst AM, Alexander BS, Wood MD () Heterogeneous 3H-rauwolscine binding sites in rat cortex: two alpha2-adrenoreceptor subtypes or an additional non-adrenergic interaction? Life Sci –92PubMedGoogle Scholar
  5. Brown CM, MacKinnon AC, McGrath JC, Spedding M, Kilpatrick AT () α2-adrenoceptors subtypes and imidazoline-like binding sites in the rat brain. Br J Pharmacol –PubMedGoogle Scholar
  6. Bylund DB () Subtypes of α2-adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci –Google Scholar
  7. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U () IV. International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev –PubMedGoogle Scholar
  8. Bylund DB, Martinez JR () Post-synaptic localization of α2-adrenergic receptors in rat submandibular gland. J Neurosci –PubMedGoogle Scholar
  9. Bylund DB, Ray-Prenger C, Murphy TJ () Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther –PubMedGoogle Scholar
  10. Connaughton S, Docherty R () Functional evidence for heterogeneity of peripheral prejunctional α2-adrenoceptors. Br J Pharmacol –Google Scholar
  11. Gleason MM, Hieble JP () The α2-adrenoceptors of the human retinoblastoma cell line (Y79) may represent an additional example for the α2C-adrenoceptor. Br J Pharmacol –PubMedGoogle Scholar
  12. Gold MS, Redmond DE, Kleber HD () Clonidine blocks acute opiate withdrawal symptoms. Lancet –PubMedGoogle Scholar
  13. Goldberg MR, Robertson D () Yohimbine: a pharmacological probe for the study of the α2-adrenoreceptor. Pharmacol Rev –PubMedGoogle Scholar
  14. Hieble JP, Sulpicio AC, Nichols AJ, Willette RN, Ruffulo RR () Pharmacologic characterization of SK&F , a novel alpha-2 adrenoceptor antagonist which discriminates between pre-and postjunctional alpha-2 adrenoceptors. J Pharm Exp Ther –Google Scholar
  15. Hieble JP, Ruffolo RR Jr, Sulpicio AC () Functional subclassification of α2-adrenoreceptors. Pharmacol Commun –97Google Scholar
  16. Hieble JP, Ruffolo RR Jr, Sulpicio AC, Naselsky DP, Conway TM, Ellis C, Swift AM, Ganguli S, Bergsma DJ () Subclassification and nomenclature of α1-and α2-adrenoceptors. In: Jucker E (ed) Progress in Drug Research. Birkhäuser Verlag, pp 81–Google Scholar
  17. Kobinger W, Walland A () Investigations into the mechanism of the hypotensive effect of 2-(2,6-dichlorphenylamino)imidazoline-HCl. Eur J Pharmacol –PubMedGoogle Scholar
  18. Langer SZ () Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol –PubMedGoogle Scholar
  19. Langer SZ () Presynaptic regulation of the release of catecholamines. Pharmacol Rev –Google Scholar
  20. Marjamäki A, Luomala K, Ala-Uotila S, Scheinin M () Use of recombinant human α2-adrenoceptors to characterize subtype selectivity of antagonist binding. Eur J Pharmacol, Mol Pharmacol Sect –Google Scholar
  21. McCall RB () Role of neurotransmitters in the central regulation of the cardiovascular system. Progr Drug Res –84Google Scholar
  22. Michel AD, Loury DN, Withing RL () Differences between the α2-adrenoceptor in rat submaxillary gland and the α2A-and α2B-adrenoceptor subtypes. Br J Pharmacol –PubMedGoogle Scholar
  23. Murphy TJ, Bylund DB () Characterization of alpha-2 adrenergic receptors in the OK cell, an opossum kidney cell line. J Pharmacol Exp Ther –PubMedGoogle Scholar
  24. Perry BD, U'Prichard DC () [3H]rauwolscine (α-yohimbine): a specific radioligand for brain α2-adrenergic receptors. Eur J Pharmacol –PubMedGoogle Scholar
  25. Pimoule C, Scatton B, Langer SZ () [3H]RX a new antagonist ligand labels α2-adrenoceptors in the rat brain cortex. Eur J Pharmacol –85PubMedGoogle Scholar
  26. Rand MJ, Wilson J () Mechanisms of the pressor and depressor actions of St (2-(2,6-dichlorophenylaminoimidazoline hydrochloride) (Catapres®). Eur J Pharmacol –33PubMedGoogle Scholar
  27. Ruffulo RR () α2-adrenoceptor agonists and antagonists. Neurotransmissions 6 (2):1–5Google Scholar
  28. Ruffulo RR, Nichols AJ, Hieble JP () Functions mediated by alpha-2 adrenergic receptors. Humana Press, Clifton, pp –Google Scholar
  29. Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP () Pharmacologic and therapeutic applications of α2-adrenoceptor subtypes. Annu Rev Pharmacol Toxicol –PubMedGoogle Scholar
  30. Satoh M, Takayanagi I () Identification and characterization of the α2D-adrenoceptor subtype in single cells prepared from guinea pig tracheal smooth muscle. Japan J Pharmacol –Google Scholar
  31. Starke K () Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol –PubMedGoogle Scholar
  32. Summers RJ, Barnett DB, Nahorski SR () Characteristics of adrenoceptors in homogenates of human cerebral cortex labelled with (3H)-rauwolscine. Life Sci –PubMedGoogle Scholar
  33. Takano Y, Takano M, Yaksh TL () The effect of intrathecally administered imiloxan and WB possible role of α2-adrenoceptor subtypes in the spinal cord. Eur J Pharmacol –PubMedGoogle Scholar
  34. U'Prichard, DC, Greenberg DA, Snyder SH () Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors. Mol Pharmacol –PubMedGoogle Scholar
  35. U'Prichard DC, Bechtel WD, Rouot B, Snyder SH () Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: Effect of 6-hydroxydopamine. Mol Pharmacol –60Google Scholar
  36. U'Prichard DC, Reisine TD, Mason ST, Fibiger MC, Yamamura HI () Modulation of rat brain α-and β-adrenergic receptor populations by lesion of the dorsal noradrenergic bundle. Brain Res. –PubMedGoogle Scholar
  37. Uhlén S, Wikberg JES () Spinal cord α2-adrenoceptors are of the α2A-subtype: comparison with α2A-and α2B-adrenoceptors in rat spleen, cerebral cortex and kidney using [3H]-RX ligand binding. Pharmacol Toxicol –Google Scholar

References

  1. Langer SZ () Presynaptic regulation of the release of catecholamines. Pharmacol Rev –Google Scholar
  2. Raiteri M, et al. () In: Handbook of Neurochemistry, Vol. 6, Plenum Publishing Corporation, New York, pp –Google Scholar
  3. Starke K () Presynaptic receptors. Ann. Rev. Pharmacol. Toxicol. –30Google Scholar
  4. Zahniser NR, et al. () In: Chemical and Functional Assays of Receptor Binding, , Short Course 1, Syllabus, published by Society for Neuroscience, Washington D.C., pp 73–81Google Scholar

References

  1. Alemany R, Olmos G, Escriba PV, Menargues A, Obach R, Garcia-Sevilla JA () LSL, , a selective ligand for imidazoline I2 receptors, on glial fibrillary acidic protein concentration. Eur J Pharmacol –PubMedGoogle Scholar
  2. Alemany R, Olmos G, Garcia-Sevilla JA () Labeling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)imidazoline (2-BFI) in rat brain and liver. Characterization, regulation and relation to monoamine oxidase enzymes. Naunyn-Schmiedeberg's Arch Pharmacol –47Google Scholar
  3. Atlas D () Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of α2-adrenergic receptor activity. Biochem Pharmacol –PubMedGoogle Scholar
  4. Atlas D, Burstein Y () Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem –PubMedGoogle Scholar
  5. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P (). The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. Eur J Pharmacol –9PubMedGoogle Scholar
  6. Brown CM, MacKinnon AC, Redfern WS, William A, Linton C, Stewart M, Clague RU, Clark R, Spedding M () RS A selective, high affinity ligand for I2 imidazoline receptors. Br J Pharmacol –PubMedGoogle Scholar
  7. Bousquet P () Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol 26/Suppl 2:S1–S6PubMedGoogle Scholar
  8. Bousquet P () Imidazoline receptors: how many, where and why? Naunyn-Schmiedeberg's Arch Pharmacol , Suppl 1, R Google Scholar
  9. Chan SLF, Atlas D, James RFL, Morgan NG () The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans. Br J Pharmacol –PubMedGoogle Scholar
  10. Dontenwill M, Molines A, Verdun A, Bricca G, Belcourt A, Bousquet P () A circulating imidazoline-like substance cross-reacts with anti-clonidine antibodies: high levels in hypertensive patients. Fundam Clin Pharmacol 6, Suppl sGoogle Scholar
  11. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VC, Dillon MP () 'seeing through a glass darkly': casting light on imidazoline ‘I’ sites. Trends Pharmacol Sci –PubMedGoogle Scholar
  12. Ernsberger P, Meeley MP, Mann JJ, Reis DJ () Clonidine binds to imidazoline binding sites as well as α2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol –13PubMedGoogle Scholar
  13. Ernsberger P, Meeley MP, Reis DJ () An endogenous substance with clonidine-like properties: selective binding to imidazole sites in the ventrolateral medulla. Brain Res –PubMedGoogle Scholar
  14. Ernsberger P, Giuliano R, Willette RN, Reis DJ () Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharm Exp Ther –Google Scholar
  15. Ernsberger PR, Westbrooks KL, Christen MO, Schäfer SG () A second generation of centrally acting antihypertensive agents act on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 20, Suppl 4:S1–S10Google Scholar
  16. Ernsberger P, Piletz JE, Graff LM, Graves ME () Optimization of radioligand binding assays for I1 imidazoline sites. Ann New York Acad Sci –Google Scholar
  17. Ernsberger P, Friedman JE, Koletsky RJ () The I1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J Hypertens/Suppl S9–S23Google Scholar
  18. Gonzalez C, Regunathan S, Reis DJ, Estrada C () Agmatine, an endogenous modulator of noradrenergic transmission in the rat tail artery. Br J Pharmacol –PubMed
Источник: [cromwellpsi.com]
, ZD Soft Video Recorder 1.0.3.0 serial key or number

  • Crystallization Behavior and Relaxation Dynamics of Supercooled S‑Ketoprofen and the Racemic Mixture along an Isochrone

    DEFF Research Database (Denmark)

    Adrjanowicz, Karolina; Kaminski, Kamil; Paluch, Marian

    In this paper, we study crystallization behavior and molecular dynamics in the supercooled liquid state of the pharmaceutically important compound ketoprofen at various thermodynamic conditions. Dielectric relaxation for a racemic mixture was investigated in a wide range of temperatures and press

  • Enhancement of bioavailability of ketoprofen using dry elixir as a novel dosage form.

    cromwellpsi.com (United States)

    Ahn, H J; Kim, K M; Kim, C K

    To enhance the dissolution rate and bioavailability of poorly water-soluble ketoprofen, a novel oral dosage form of ketoprofen, termed ketoprofen dry elixir, was developed by the spray-drying technique. Ketoprofen, dextrin, and sodium lauryl sulfate were dissolved in an ethanol-water mixture ( w/w) and thereafter spray-dried to form the ketoprofen dry elixir. Comparative studies on the in vitro dissolution and in vivo adsorption of ketoprofen in the form of dry elixir and powder were carried out. Ketoprofen in the dry elixir completely dissolved within 5 min. On the other hand, only about % of ketoprofen powder alone dissolved during 60 min. The initial dissolution rate of ketoprofen in the dry elixir markedly increased in distilled water at 37 degrees C, becoming fourfold higher than that of ketoprofen powder alone. The maximal plasma concentration of ketoprofen (Cmax) and the area under the concentration-time curve from zero to 8 hr (AUC hr) after the oral administration of dry elixir increased about ( versus micrograms/ml) and ( versus micrograms hr/ml) fold compared with powder alone. It was obvious that ketoprofen dry elixir might be a useful solid dosage form to improve the dissolution rate and bioavailability of poorly water-soluble ketoprofen.

  • Optical Detection of Ketoprofen by Its Electropolymerization on an Indium Tin Oxide-Coated Optical Fiber Probe.

    cromwellpsi.com (United States)

    Bogdanowicz, Robert; Niedziałkowski, Paweł; Sobaszek, Michał; Burnat, Dariusz; Białobrzeska, Wioleta; Cebula, Zofia; Sezemsky, Petr; Koba, Marcin; Stranak, Vitezslav; Ossowski, Tadeusz; Śmietana, Mateusz

    In this work an application of optical fiber sensors for real-time optical monitoring of electrochemical deposition of ketoprofen during its anodic oxidation is discussed. The sensors were fabricated by reactive magnetron sputtering of indium tin oxide (ITO) on a cm-long core of polymer-clad silica fibers. ITO tuned in optical properties and thickness allows for achieving a lossy-mode resonance (LMR) phenomenon and it can be simultaneously applied as an electrode in an electrochemical setup. The ITO-LMR electrode allows for optical monitoring of changes occurring at the electrode during electrochemical processing. The studies have shown that the ITO-LMR sensor’s spectral response strongly depends on electrochemical modification of its surface by ketoprofen. The effect can be applied for real-time detection of ketoprofen. The obtained sensitivities reached over nm/M (nm·mg −1 ·L) and 16, a.u./M (a.u.·mg −1 ·L) for resonance wavelength and transmission shifts, respectively. The proposed method is a valuable alternative for the analysis of ketoprofen within the concentration range of ⁻ μg mL −1 , and allows for its determination at therapeutic and toxic levels. The proposed novel sensing approach provides a promising strategy for both optical and electrochemical detection of electrochemical modifications of ITO or its surface by various compounds.

  • Effects of a new foam formulation of ketoprofen lysine salt in experimental models of inflammation and hyperalgesia.

    cromwellpsi.com (United States)

    Daffonchio, L; Bestetti, A; Clavenna, G; Fedele, G; Ferrari, M P; Omini, C

    The anti-inflammatory and analgesic profile of a new topical foam formulation of ketoprofen lysine salt (CAS , Artrosilene Schiuma, KLS-foam) was characterized in comparison with marketed gel formulations containing KLS (KLS-gel) or diclofenac diethylammonium salt (DCF-gel). KLS-foam dose-dependently inhibited oedema formation and hyperalgesia induced by subplantar injection of carrageenan or substance P, being more potent than KLS-gel. At equieffective anti-inflammatory doses, KLS-foam provided a more pronounced analgesic effect than DCF-gel. KLS-foam also markedly inhibited exudate formation and prostaglandin production induced by subcutaneous implantation of carrageenan soaked sponges. In carrageenan induced paw inflammation, KLS-foam provided the same anti-inflammatory effect as orally administered KLS, but induced significantly less gastric damages. Oral administration of KLS resulted in sustained systemic absorption of ketoprofen, whereas after topical application of KLS-foam no appreciable ketoprofen plasma levels were detected. These data support the anti-inflammatory and particularly the analgesic effectiveness of the new foam formulation of KLS, a finding that, together with the high gastric tolerability, further emphasizes the usefulness of KLS-foam in the treatment of localized flogistic diseases and associated pain.

  • Acoustic and thermal anomalies in a liquid-glass transition of racemic S(+)-R(-) ketoprofen

    cromwellpsi.com (United States)

    Shibata, Tomohiko; Takayama, Haruki; Kim, Tae Hyun; Kojima, Seiji

    Acoustic and thermal properties of pharmaceutical racemic S(+)-R(-) ketoprofen were investigated in wide temperature range including glassy, supercooled liquid and liquid states by Brillouin scattering and temperature modulated DSC. Sound velocity and acoustic attenuation exhibited clear changes at K indicating a liquid-glass transition and showed the typical structural relaxation above Tg. The high value of the fragility index m = 71 was determined by the dispersion of the complex heat capacity. New relaxation map was suggested in combination with previous study of dielectric measurement.

  • Efeitos da associação entre pequenas doses subaracnóideas de morfina e cetoprofeno venoso e oral em pacientes submetidas à cesariana Efectos de la asociación entre pequeñas dosis subaracnóideas de morfina y cetoprofeno venoso y oral en pacientes sometidas a cesariana Effects of low spinal morphine doses associated to intravenous and oral ketoprofen in patients submitted to cesarean sections

    Directory of Open Access Journals (Sweden)

    Eliana Marisa Ganem

    de efectos colaterales en pacientes sometidas a cesariana, bajo anestesia subaracnóidea con bupivacaína hiperbárica y morfina en las dosis de 0,05 mg y 0,1 mg, asociadas al cetoprofeno por las vías venosa y oral. MÉTODO: Participaron del estudio 60 gestantes de término, estado físico ASA I y II, que fueron sometidas a cesariana electiva. Las pacientes fueron divididas en dos grupos: grupo 1 - morfina 0,1 mg, grupo 2 - 0,05 mg, asociada a 15 mg de bupivacaína hiperbárica. Todas recibieron cetoprofeno ( mg por vía venosa en el per-operatorio y por vía oral a cada 8 horas en el primer día del pos-operatorio. Las pacientes fueron evaluadas 6, 12 y 24 horas después del término de la cirugía, con relación a la intensidad del dolor y presencia de efectos colaterales (sedación, prurito, náusea y vómito. La presencia de estos últimos también fue evaluada en el per-operatorio. RESULTADOS: Ambos grupos fueron idénticos cuanto a los datos antropométricos y la duración de la cirugía y de la anestesia. También fueron homogéneos con relación a la intensidad del dolor pos-operatorio y a la presencia de prurito, sedación, náusea y vómito. CONCLUSIONES: La morfina, en las dosis de 0,05 mg y 0,1 mg administradas en el espacio subaracnóideo, asociada al cetoprofeno por las vías venosa y oral, presentó la misma calidad de analgesia pos-operatoria y determinó la misma ocurrencia de efectos cromwellpsi.comOUND AND OBJECTIVES: Low spinal morphine doses are effective in relieving postoperative pain of patients submitted to Cesarean sections, with low incidence of side-effects. This study aimed at evaluating postoperative analgesia and the incidence of side-effects in patients submitted to Cesarean sections under spinal anesthesia with hyperbaric bupivacaine and mg and mg morphine associated to intravenous and oral ketoprofen. METHODS: Sixty pregnant women, physical status ASA I and II, undergoing elective Cesarean sections, were divided in

  • Sibutramine in weight control: a dose-ranging, efficacy study.

    cromwellpsi.com (United States)

    Weintraub, M; Rubio, A; Golik, A; Byrne, L; Scheinbaum, M L

    We tested the safety and efficacy of sibutramine, 5 and 20 mg, and placebo on weight loss. Medication was added to caloric restriction, behavior modification, and exercise in a parallel-group, double-blind clinical trial. Participants were % to % of ideal body weight and in good health. The study lasted 12 weeks over Thanksgiving, Christmas, and New Year's Day. Weight loss during 8 weeks of study medication was: placebo, +/- kg (n = 19); 5 mg sibutramine, +/- kg (n = 18); and 20 mg sibutramine, +/- kg (n = 18) (p less than sibutramine, 5 and 20 mg, versus placebo; p less than sibutramine, 20 mg versus 5 mg). There is a significant dose-effect relationship. Five participants left the study before completion, all because of adverse events; placebo (one patient), 5 mg sibutramine (one patient), and 20 mg sibutramine (three patients). Sleep difficulties were noted by eight participants (20 mg sibutramine, seven patients; 5 mg, one patient; and placebo, no patients). Six of 21 participants receiving 20 mg complained of irritability, unusual impatience, or "excitation." Sibutramine, 5 and 20 mg, added to a multimodal program assisted participants in losing weight.

  • Presurgical ketoprofen, but not morphine, dipyrone, diclofenac or tenoxicam, preempts post-incisional mechanical allodynia in rats

    Directory of Open Access Journals (Sweden)

    Prado W.A.

    Full Text Available The treatment of pain before it initiates may prevent the persistent pain-induced changes in the central nervous system that amplify pain long after the initial stimulus. The effects of pre- or postoperative intraperitoneal administration of morphine (2 to 8 mg/kg, dipyrone (40 and 80 mg/kg, diclofenac (2 to 8 mg/kg, ketoprofen (10 and 20 mg/kg, and tenoxicam (10 and 20 mg/kg were studied in a rat model of post-incisional pain. Groups of 5 to 8 male Wistar rats ( g were used to test each drug dose. An incision was made on the plantar surface of a hind paw and the changes in the withdrawal threshold to mechanical stimulation were evaluated with Von Frey filaments at 1, 2, 6 and 24 h after the surgery. Tenoxicam was given 12 or 6 h preoperatively, whereas the remaining drugs were given 2 h or 30 min preoperatively. Postoperative drugs were all given 5 min after surgery. No drug abolished allodynia when injected before or after surgery, but thresholds were significantly higher than in control during up to 2 h following ketoprofen, 6 h following diclofenac, and 24 h following morphine, dipyrone or tenoxicam when drugs were injected postoperatively. Significant differences between pre- and postoperative treatments were obtained only with ketoprofen administered 30 min before surgery. Preoperative (2 h intraplantar, but not intrathecal, ketoprofen reduced the post-incisional pain for up to 24 h after surgery. It is concluded that stimuli generated in the inflamed tissue, rather than changes in the central nervous system are relevant for the persistence of pain in the model of post-incisional pain.

  • Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.

    cromwellpsi.com (United States)

    Marchand, Sandrine; Lamarche, Isabelle; Gobin, Patrice; Couet, William

    The aim of this study was to evaluate the effect of colistin methanesulphonate (CMS) dose on CMS and colistin pharmacokinetics in rats. Three rats per group received an intravenous bolus of CMS at a dose of 5, 15, 30, 60 or mg/kg. Arterial blood samples were drawn at 0, 5, 15, 30, 60, 90, , and min. CMS and colistin plasma concentrations were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters of CMS and colistin were calculated by non-compartmental analysis. Linear relationships were observed between CMS and colistin AUCs to infinity and CMS doses, as well as between CMS and colistin C(max) and CMS doses. CMS and colistin pharmacokinetics were linear for a range of colistin concentrations covering the range of values encountered and recommended in patients even during treatment with higher doses.

  • Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosingrange criteria.

    cromwellpsi.com (United States)

    Hew, M; Gillman, A; Sutherland, M; Wark, P; Bowden, J; Guo, M; Reddel, H K; Jenkins, C; Marks, G B; Thien, F; Rimmer, J; Katsoulotos, G P; Cook, M; Yang, I; Katelaris, C; Bowler, S; Langton, D; Wright, C; Bint, M; Yozghatlian, V; Burgess, S; Sivakumaran, P; Yan, K Y; Kritikos, V; Peters, M; Baraket, M; Aminazad, A; Robinson, P; Jaffe, A; Powell, H; Upham, J W; McDonald, V M; Gibson, P G

    Omalizumab (Xolair) dosing in severe allergic asthma is based on serum IgE and bodyweight. In Australia, patients eligible for omalizumab but exceeding recommended ranges for IgE ( IU/mL) and bodyweight ( kg) may still receive a ceiling dose of mg/4 weeks. About 62% of patients receiving government-subsidized omalizumab are enrolled in the Australian Xolair Registry (AXR). To determine whether AXR participants above the recommended dosingranges benefit from omalizumab and to compare their response to within-range participants. Data were stratified according to doserange status (above-range or within-range). Further sub-analyses were conducted according to the reason for being above the dosingrange (IgE only vs. IgE and weight). Data for participants were analysed. About 55 (31%) were above recommended dosing criteria; other characteristics were similar to within-range participants. Above-range participants had higher baseline IgE [ (IQR , ) IU/mL vs. (IQR , ) IU/mL] and received higher doses of omalizumab [ (IQR , ) mg] compared to within-range participants [ (IQR, , ) mg]. At 6 months, improvements in Juniper 5-item Asthma Control Questionnaire (ACQ-5, down to for above-range, down to for within-range, P omalizumab have significantly improved symptom control, quality of life and lung function to a similar degree to within-range participants, achieved without dose escalation above mg. © John Wiley & Sons Ltd.

  • Two factors influencing dose reconstruction in low doserange: the variability of BKG intensity on one individual and water content

    International Nuclear Information System (INIS)

    Zhang, Tengda; Zhang, Wenyi; Zhao, Zhixin; Zhang, Haiying; Ruan, Shuzhou; Jiao, Ling

    A fast and accurate retrospective dosimetry method for the triage is very important in radiation accidents. Electron paramagnetic resonance (EPR) fingernail dosimetry is a promising way to estimate radiation dose. This article presents two factors influencing dose reconstruction in low doserange: the variability of background signal (BKG) intensity on one individual and water content. Comparing the EPR spectrum of dried and humidified fingernail samples, it is necessary to add a procedure of dehydration before EPR measurements, so as to eliminate the deviation caused by water content. Besides, the BKGs of different fingers' nails are not the same as researchers thought previously, and the difference between maximum and minimum BKG intensities of one individual can reach %. Meanwhile, the variability of the BKG intensity among individuals is large enough to impact precise dose reconstruction. Water within fingernails and instability of BKG are two reasons that cause the inaccuracy of radiation dose reconstruction in low-dosage level. (authors)

  • Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax.

    cromwellpsi.com (United States)

    Kheradmandnia, Soheila; Vasheghani-Farahani, Ebrahim; Nosrati, Mohsen; Atyabi, Fatemeh

    Solid lipid nanoparticles (SLNs) have been proposed as suitable colloidal carriers for delivery of drugs with limited solubility. Ketoprofen as a model drug was incorporated into SLNs prepared from a mixture of beeswax and carnauba wax using Tween 80 and egg lecithin as emulsifiers. The characteristics of the SLNs with various lipid and surfactant composition were investigated. The mean particle size of drug-loaded SLNs decreased upon mixing with Tween 80 and egg lecithin as well as upon increasing total surfactant concentration. SLNs of 75 ± 4 nm with a polydispersity index of ± were obtained using 1% (vol/vol) mixed surfactant at a ratio of Tween 80 to egg lecithin. The zeta potential of these SLNs varied in the range of to (mV), suggesting the presence of similar interface properties. High drug entrapment efficiency of 97% revealed the ability of SLNs to incorporate a poorly water-soluble drug such as ketoprofen. Differential scanning calorimetry thermograms and high-performance liquid chromatographic analysis indicated the stability of nanoparticles with negligible drug leakage after 45 days of storage. It was also found that nanoparticles with more beeswax content in their core exhibited faster drug release as compared with those containing more carnauba wax in their structure. Copyright © Elsevier Inc. All rights reserved.

  • Pengaruh Penambahan Sodium Lauril Sulfat (Sls) Sebagai Surfaktan Terhadap Sifat Fisik Dan Uji Disolusi Tablet Ketoprofen

    OpenAIRE

    Pratama, Adithya Wahyu; Siswanto, Agus; Suparman, Suparman

    Ketoprofen (acid 2-(3-benzoilfenil) propanoat) was derivated of propionat acid which has analgesic, antipyretic, and anti-inflammatory with poor solubillity in water. This research allowed to increase the dissolution rate of ketoprofen tablets and effect on the physical characteristic by adding sodium lauril sulfat as surfactant. Sodium lauryl sulfat is a surfactant that can be used to improve wetting and dissolution rate. This study was done with make four formula of ketoprofen tablets by d

  • Comparative chemoreactome analysis of dexketoprofen, ketoprofen, and diclofenac

    Directory of Open Access Journals (Sweden)

    I. Yu. Torshin

    Full Text Available Cyclooxygenase-2 (COX-2 is the main targeted protein of non-steroidal anti-inflammatory drugs (NSAID; nevertheless, the latter substantially differ in pharmacological cromwellpsi.comive: to establish the spectrum of pharmacological actions of dexketoprofen, ketoprofen, and diclofenac, by using a chemoreactome cromwellpsi.comal and methods. A chemoinformation analysis was used to determine a list of the chemical structures closest to dexketoprofen. For each molecule, the investigators extracted the results of experimental measurements of the rheological properties of this molecule from databases and a chemoreactome analysis was carried out. The comparative chemoreactome analysis of the molecule of dexketoprofen and control molecules (ketoprofen, diclofenac could assess the biological activity of the studied cromwellpsi.coms and discussion. Unlike the molecules of comparison, dexketoprofen was found to be able to accumulate mainly in muscles, adipose tissue, and adrenal glands. The anti-inflammatory and analgesic effect of dexketoprofen can be carried out via modulation not only of the metabolism of prostaglandins, but also that of leukotrienes and encephalins, as well as via inhibition of metalloproteinases and glutamate receptors. In addition, the analysis showed a considerable difference in the interaction profiles of dexketoprofen, ketoprofen, and diclofenac with cytochrome P enzymes. Dexketoprofen can enhance the efficacy of anti-arrhythmic and antiadrenergic agents, whereas ketoprofen and diclofenac are able to negatively affect the metabolism of omega-3 polyunsaturated fatty acids and vitamin cromwellpsi.comsion. The chemoreactome analysis could identify the promising vasodilatory, antiplatelet, antidiabetic, and antitumor effects of dexketoprofen in addition to its main action. 

  • TRADOS - an air trajectory dose model for long range transport of radioactive release to the atmosphere

    International Nuclear Information System (INIS)

    Rossi, J.; Valkama, I.

    A model for estimating radiation doses resulting from long range atmospheric transport of released radionuclides in accidents is precented. The model (TRADOS) is able to treat changing diffusion conditions. For example the plume can be exposed to temporary rain, changes in turbulence and mixing depth. This can result in considerable changes in individual doses. The method is applied to an example trajectory and the doses caused by a serious reactor accident are calculated

  • Multi-spectroscopic method study the interaction of anti-inflammatory drug ketoprofen and calf thymus DNA and its analytical application

    cromwellpsi.com (United States)

    Guo, Hongqin; Cai, Changqun; Gong, Hang; Chen, Xiaoming

    Interactions of the anti-inflammatory drug ketoprofen with calf thymus DNA (ctDNA) in aqueous solution have been studied by multi-spectroscopic method including resonance light scattering (RLS) technique, ultraviolet spectra (UV), 1H NMR, etc. The characteristics of RLS spectra, the effective factors and optimum conditions of the reaction have been unequivocally investigated. Mechanism investigations have shown that ketoprofen can bind to ctDNA by groove binding and form large particles, which resulted in the enhancement of RLS intensity. In Critic acid-Na 2HPO 4 buffer (pH = ), ketoprofen has a maximum peak nm and the RLS intensity is remarkably enhanced by trace amount of ctDNA due to the interaction between ketoprofen and ctDNA. The enhancement of RLS signal is directly proportional to the concentration of ctDNA in the range of × 10 × 10 -5 mol/L, and its detection limit (3 σ) is × 10 -9 mol/L. The method is simple, rapid, practical and relatively free from interference generated by coexisting substance, and was applied to the determination of trace amounts of nucleic acid in synthetic samples with satisfactory results.

  • A randomized, double blind comparison of pethidine and ketoprofen as adjuvants for lignocaine in intravenous regional anaesthesia

    Directory of Open Access Journals (Sweden)

    Sameer N. Desai

    Full Text Available BACKGROUND AND OBJECTIVES: A review of all the adjuncts for intravenous regional anaesthesia concluded that there is good evidence to recommend NonSteroidal Anti-Inflammatory agents and pethidine in the dose of 30 mg dose as adjuncts to intravenous regional anaesthesia. But there are no studies to compare pethidine of 30 mg dose to any of the NonSteroidal Anti-Inflammatory agents. METHODS: In a prospective, randomized, double blind study, 45 patients were given intravenous regional anaesthesia with either lignocaine alone or lignocaine with pethidine 30 mg or lignocaine with ketprofen mg. Fentanyl was used as rescue analgesic during surgery. For the first 6 h of postoperative period analgesia was provided by fentanyl injection and between 6 and 24 h analgesia was provided by diclofenac tablets. Visual analogue scores for pain and consumption of fentanyl and diclofenac were compared. RESULTS: The block was inadequate for one case each in lignocaine group and pethidine group, so general anaesthesia was provided. Time for the first dose of fentanyl required for postoperative analgesia was significantly more in pethidine and ketoprofen groups compared to lignocaine group ( ± and ± vs. ± min respectively. Total fentanyl consumption in first 6 h of postoperative period was less in pethidine and ketoprofen groups compared to lignocaine group ( ± mcg, ± mcg vs. ± mcg respectively. Consumption of diclofenac tablets was ± , ± and ± in the control, pethidine and ketoprofen group respectively, which was statistically not significant. Side effects were not significantly different between the groups. CONCLUSION: Both pethidine and ketoprofen are equally effective in providing postoperative analgesia up to 6 h, without significant difference in the side effects and none of the adjuncts provide significant analgesia after 6 h.

  • Applichation of the sulphate ceric dosimetric in the high dosesrange

    International Nuclear Information System (INIS)

    Prieto Miranda, F.

    The ceric-cerous dosimetric system is one of the system more employed in the high dose dosimetry. The spectrophotometric procedure to measure the ceric-concentration is an usual analityc method to determine the absorbed dose. On the other hand, due at increase employ of the irradiation process control. In this paper is realized the ceric-cerous dosimetric calibration in the doserange of 0,6 - 5 kGy and the application in the irradiation process control to differents absorbed dose values

  • Properties of Wide-dose-range GafChromic Films for Synchrotron Radiation Facility

    International Nuclear Information System (INIS)

    Nariyama, Nobuteru

    GafChromic films have been used at SPring-8 to detect the intensively irradiated parts and protect them from damage by being covered with shield or moved. To extend the usable doserange more widely, a new type of sensitive film EBT was investigated for the introduction. Calibration curves were obtained irradiated with 60Co γ rays and compared with those of other GafChromic films. For the application, these films were set in the white x-ray hutch and the dose distribution was measured. Ratio of doses given by EBT and XT-R indicated the degree of the photon spectrum hardness, which depended on the positions. As a result, doserange from 50 mGy to kGy became available for dose distribution measurements, and a set of films having different energy responses was found to give information of photon spectra

  • Development of dose monitoring system applicable to various radiations with wide energy ranges

    International Nuclear Information System (INIS)

    Sato, Tatsuhiko; Satoh, Daiki; Endo, Akira; Yamaguchi, Yasuhiro

    A new inventive radiation dose monitor, designated as DARWIN (Dose monitoring system Applicable to various Radiations with WIde energy raNges), has been developed for monitoring doses in workspaces and surrounding environments of high energy accelerator facilities. DARWIN is composed of a phoswitch-type scintillation detector, which consists of liquid organic scintillator BCA coupled with ZnS(Ag) scintillation sheets doped with 6 Li, and a data acquisition system based on a Digital-Storage-Oscilloscope. Scintillations from the detector induced by thermal and fast neutrons, photons and muons were discriminated by analyzing their waveforms, and their light outputs were directly converted into the corresponding doses by applying the G-function method. Characteristics of DARWIN were studied by both calculation and experiment. The calculated results indicate that DARWIN gives reasonable estimations of doses in most radiation fields. It was found from the experiment that DARWIN has an excellent property of measuring doses from all particles that significantly contribute to the doses in surrounding environments of accelerator facilities - neutron, photon and muon with wide energy ranges. The experimental results also suggested that DARWIN enables us to monitor small fluctuation of neutron dose rates near the background-level owing to its high sensitivity. (author)

    • Источник: [cromwellpsi.com]
    ZD Soft Video Recorder 1.0.3.0 serial key or number

    It uses both game and video technologies to tell the universal story of an individuals journey towards enlightenment. nbsp;ppThe Night Journey is available worldwide at gameinnovationlab. itch.

    .

    What’s New in the ZD Soft Video Recorder 1.0.3.0 serial key or number?

    Screen Shot

    System Requirements for ZD Soft Video Recorder 1.0.3.0 serial key or number

    Related Posts

    About Author

    admin

    Add a Comment

    Your email address will not be published. Required fields are marked *